{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Recombinant+Influenza+Vaccine",
    "query": {
      "intervention": "Recombinant Influenza Vaccine"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 106,
    "total_pages": 11,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Recombinant+Influenza+Vaccine&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-29T02:23:50.059Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT05513053",
      "title": "Study With Quadrivalent Recombinant Influenza Vaccine (RIV4) in Participants 9 Through 49 Years of Age.",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Influenza Immunization"
      ],
      "interventions": [
        {
          "name": "Quadrivalent Recombinant influenza vaccine (RIV4) season/2022-2023/NH",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Sanofi Pasteur, a Sanofi Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "9 Years",
        "maximum_age": "49 Years",
        "sex": "ALL",
        "summary": "9 Years to 49 Years"
      },
      "enrollment_count": 1308,
      "start_date": "2022-10-27",
      "completion_date": "2023-10-27",
      "has_results": true,
      "last_update_posted_date": "2025-09-09",
      "last_synced_at": "2026-09-29T02:23:50.059Z",
      "location_count": 21,
      "location_summary": "Birmingham, Alabama • Jonesboro, Arkansas • San Diego, California + 16 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Jonesboro",
          "state": "Arkansas"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Sioux City",
          "state": "Iowa"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05513053"
    },
    {
      "nct_id": "NCT01995695",
      "title": "Safety and Immunogenicity of a Live Attenuated H7N9 Influenza Virus Vaccine in Healthy Adults",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Influenza A Virus, H7N9 Subtype"
      ],
      "interventions": [
        {
          "name": "Live attenuated H7N9 A/Anhui/13 ca influenza virus vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Inactivated subvirion H7N9 influenza vaccine",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "49 Years",
        "sex": "ALL",
        "summary": "18 Years to 49 Years"
      },
      "enrollment_count": 48,
      "start_date": "2013-10",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2016-07-27",
      "last_synced_at": "2026-09-29T02:23:50.059Z",
      "location_count": 1,
      "location_summary": "Rochester, New York",
      "locations": [
        {
          "city": "Rochester",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01995695"
    },
    {
      "nct_id": "NCT00474526",
      "title": "A Study to Evaluate Safety and Immune Response of Novartis Meningococcal ACWY Vaccine In Infants",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Meningitis, Meningococcal"
      ],
      "interventions": [
        {
          "name": "Meningococcal ACWY Conjugate Vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "DTaP-IPV-HBV",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Hib",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Rotavirus",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Pneumococcal 7-valent Conjugate Vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "HAV",
          "type": "BIOLOGICAL"
        },
        {
          "name": "MMR-V",
          "type": "BIOLOGICAL"
        },
        {
          "name": "DTaP",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Novartis Vaccines",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "2 Months",
        "maximum_age": "2 Months",
        "sex": "ALL",
        "summary": "2 Months to 2 Months"
      },
      "enrollment_count": 4545,
      "start_date": "2007-03",
      "completion_date": "2009-11",
      "has_results": true,
      "last_update_posted_date": "2014-03-24",
      "last_synced_at": "2026-09-29T02:23:50.059Z",
      "location_count": 53,
      "location_summary": "Bessemer, Alabama • Birmingham, Alabama • Downey, California + 43 more",
      "locations": [
        {
          "city": "Bessemer",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Downey",
          "state": "California"
        },
        {
          "city": "Oakland",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00474526"
    },
    {
      "nct_id": "NCT03694392",
      "title": "Flublok v. Standard Dose Vaccine Effectiveness Among Kaiser Permanente Northern California Adults 18-64 Years",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Influenza",
        "Pneumonia",
        "Lower Respiratory Tract Infection",
        "Acute Myocardial Infarction",
        "Congestive Heart Failure",
        "Stroke"
      ],
      "interventions": [
        {
          "name": "Flublok Quadrivalent",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Standard Dose Inactivated Influenza Vaccine (SD-IIV)",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Kaiser Permanente",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "64 Years",
        "sex": "ALL",
        "summary": "18 Years to 64 Years"
      },
      "enrollment_count": 2776278,
      "start_date": "2018-09-16",
      "completion_date": "2022-12-31",
      "has_results": true,
      "last_update_posted_date": "2025-04-08",
      "last_synced_at": "2026-09-29T02:23:50.059Z",
      "location_count": 1,
      "location_summary": "Oakland, California",
      "locations": [
        {
          "city": "Oakland",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03694392"
    },
    {
      "nct_id": "NCT03293498",
      "title": "Evaluation of the Safety and Immunogenicity of a Recombinant Trivalent Nanoparticle Influenza Vaccine With Matrix M-1 Adjuvant (NanoFlu)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Influenza"
      ],
      "interventions": [
        {
          "name": "NanoFlu",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Fluzone HD - Day 0",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Fluzone HD - Day 21",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Saline - Day 21",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "Novavax",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "60 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "60 Years and older"
      },
      "enrollment_count": 330,
      "start_date": "2017-09-18",
      "completion_date": "2018-10-29",
      "has_results": true,
      "last_update_posted_date": "2022-12-21",
      "last_synced_at": "2026-09-29T02:23:50.059Z",
      "location_count": 3,
      "location_summary": "Raleigh, North Carolina • Rocky Mount, North Carolina • Statesville, North Carolina",
      "locations": [
        {
          "city": "Raleigh",
          "state": "North Carolina"
        },
        {
          "city": "Rocky Mount",
          "state": "North Carolina"
        },
        {
          "city": "Statesville",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03293498"
    },
    {
      "nct_id": "NCT01147068",
      "title": "Safety and Immunogenicity of PanBlok Influenza Vaccine in Healthy Adults",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Influenza"
      ],
      "interventions": [
        {
          "name": "0.5mL Intramuscular Injection",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Protein Sciences Corporation",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "49 Years",
        "sex": "ALL",
        "summary": "18 Years to 49 Years"
      },
      "enrollment_count": 392,
      "start_date": "2010-06",
      "completion_date": "2011-10",
      "has_results": true,
      "last_update_posted_date": "2012-11-26",
      "last_synced_at": "2026-09-29T02:23:50.059Z",
      "location_count": 4,
      "location_summary": "Overland Park, Kansas • Omaha, Nebraska • Rochester, New York + 1 more",
      "locations": [
        {
          "city": "Overland Park",
          "state": "Kansas"
        },
        {
          "city": "Omaha",
          "state": "Nebraska"
        },
        {
          "city": "Rochester",
          "state": "New York"
        },
        {
          "city": "Fort Worth",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01147068"
    },
    {
      "nct_id": "NCT06695130",
      "title": "Study of a Combination Vaccine Comprised of Different Recombinant Spike Antigen Levels of a Matrix-M Adjuvanted Recombinant COVID-19 Vaccine and Recombinant Influenza Vaccine in Adult Participants 50 Years of Age and Older",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "COVID-19 Immunization",
        "Influenza Immunization"
      ],
      "interventions": [
        {
          "name": "RIV (recombinant influenza vaccine)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "rC19 (dose 1)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "RIV + rC19 (dose 1)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "RIV + rC19 (dose 2)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "RIV + rC19 (dose 3)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "RIV + rC19 (dose 4)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo (0.9% NaCl)",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "Sanofi",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "50 Years and older"
      },
      "enrollment_count": 980,
      "start_date": "2024-11-18",
      "completion_date": "2026-04-03",
      "has_results": false,
      "last_update_posted_date": "2026-05-05",
      "last_synced_at": "2026-09-29T02:23:50.059Z",
      "location_count": 12,
      "location_summary": "Phoenix, Arizona • Cerritos, California • Vista, California + 9 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Cerritos",
          "state": "California"
        },
        {
          "city": "Vista",
          "state": "California"
        },
        {
          "city": "Melbourne",
          "state": "Florida"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06695130"
    },
    {
      "nct_id": "NCT03945825",
      "title": "Flublok or Fluzone With Advax-CpG55.2 or AF03",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Influenza",
        "Influenza Immunisation"
      ],
      "interventions": [
        {
          "name": "AF03",
          "type": "DRUG"
        },
        {
          "name": "Delta Inulin-CpG55.2",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Influenza Virus Quadrivalent Inactivated Vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Quadrivalent Recombinant Seasonal Influenza Vaccine",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "45 Years",
        "sex": "ALL",
        "summary": "18 Years to 45 Years"
      },
      "enrollment_count": 241,
      "start_date": "2019-06-10",
      "completion_date": "2020-09-18",
      "has_results": true,
      "last_update_posted_date": "2025-10-14",
      "last_synced_at": "2026-09-29T02:23:50.059Z",
      "location_count": 8,
      "location_summary": "Atlanta, Georgia • Iowa City, Iowa • Baltimore, Maryland + 5 more",
      "locations": [
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Iowa City",
          "state": "Iowa"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        },
        {
          "city": "Durham",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03945825"
    },
    {
      "nct_id": "NCT00539864",
      "title": "Safety and Reactogenicity of FluBlok and Comparison of Immunogenicity, Efficacy and Effectiveness Against TIV",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Influenza"
      ],
      "interventions": [
        {
          "name": "FluBlok Influenza Vaccination",
          "type": "BIOLOGICAL"
        },
        {
          "name": "TIV (Fluzone) Influenza Vaccination",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Protein Sciences Corporation",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": "64 Years",
        "sex": "ALL",
        "summary": "50 Years to 64 Years"
      },
      "enrollment_count": 602,
      "start_date": "2007-09",
      "completion_date": "2008-04",
      "has_results": true,
      "last_update_posted_date": "2011-07-27",
      "last_synced_at": "2026-09-29T02:23:50.059Z",
      "location_count": 5,
      "location_summary": "Fresno, California • Hayward, California • Roseville, California + 2 more",
      "locations": [
        {
          "city": "Fresno",
          "state": "California"
        },
        {
          "city": "Hayward",
          "state": "California"
        },
        {
          "city": "Roseville",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "Honolulu",
          "state": "Hawaii"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00539864"
    },
    {
      "nct_id": "NCT00754455",
      "title": "Evaluate the Safety and Immunogenicity of a Seasonal Influenza VLP Vaccine (Recombinant) in Healthy Adults",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Influenza"
      ],
      "interventions": [
        {
          "name": "Influenza VLP Vaccine (recombinant)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Novavax",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "49 Years",
        "sex": "ALL",
        "summary": "18 Years to 49 Years"
      },
      "enrollment_count": 317,
      "start_date": "2008-09",
      "completion_date": "2009-03",
      "has_results": false,
      "last_update_posted_date": "2013-07-18",
      "last_synced_at": "2026-09-29T02:23:50.059Z",
      "location_count": 4,
      "location_summary": "Pembroke Pines, Florida • Kansas City, Missouri • Warwick, Rhode Island + 1 more",
      "locations": [
        {
          "city": "Pembroke Pines",
          "state": "Florida"
        },
        {
          "city": "Kansas City",
          "state": "Missouri"
        },
        {
          "city": "Warwick",
          "state": "Rhode Island"
        },
        {
          "city": "Austin",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00754455"
    }
  ]
}